TL;DR: The AdvisorShares Pure US Cannabis ETF (MSOS) gained 2.13 percent on Friday July 10, advancing to $4.5550 as the domestic cannabis sector extended weekly gains heading into the weekend. Broad momentum across multi-state operators tracks a pattern of measured institutional accumulation ahead of the August earnings window, when several high-cap MSOs are scheduled to report Q2 2026 financial results. The structural investment case for U.S. cannabis remains anchored to Schedule III reclassification reform and sustained operating improvements across the leading operators.
Market Analysis
MSOS opened Friday’s session at $4.47 and traded in a range of $4.42 to $4.57, settling near the upper end of the day’s range at $4.5550 — a gain of $0.0950 or 2.13 percent over Thursday’s close of $4.46. Volume registered at 2.43 million shares, running well below the fund’s 9.15 million share average, suggesting the advance was measured rather than volume-driven. This pattern is consistent with pre-earnings positioning rather than speculative surge activity — a constructive technical signal heading into the weekend.
The fund’s 52-week range extends from $2.48 to $7.25, placing Friday’s close at approximately 63 percent of that range’s width. The one-year return of 61.59 percent reflects the sector’s substantial recovery from mid-2025 cycle lows, while the fund’s net assets of $1.05 billion signal continued institutional participation in U.S. cannabis equity exposure.
Top two holdings — Curaleaf Holdings (CURLF) at 12.18 percent of assets and Trulieve Cannabis (TCNNF) at 9.45 percent — dominate the fund’s composition, meaning Friday’s MSOS advance is closely correlated with performance at those two bellwether operators. Curaleaf reports Q2 2026 earnings on August 5; Trulieve has not yet announced a formal reporting date, though a late-July to early-August window is consistent with historical cadence.
Broader sector names contributing to Friday’s positive tone include Green Thumb Industries (GTBIF), Verano Holdings (VRNOF), and AYR Wellness (AYRWF), all of which carry August reporting dates. The clustering of MSO earnings in the first two weeks of August creates a sequenced fundamental catalyst chain that is likely to drive elevated sector volatility relative to the current measured trading environment.
Regulatory and Market Context
The Schedule III reclassification process — initiated under the Biden administration and sustained through the current regulatory posture — continues to function as the primary structural tailwind for the domestic cannabis investment thesis. While a final DEA rule has not been published, the administrative record supporting reclassification remains intact. Federal tax reform under Section 280E, which disallows standard business deductions for cannabis operators classified as trafficking controlled substances under Schedule I, remains the single most consequential policy lever awaiting resolution.
Removal of 280E liability alone would transform the EBITDA-to-net-income bridge for most U.S. MSOs. Operators including Curaleaf and Trulieve carry the largest absolute 280E tax burden given their revenue scale. Multiple companies have flagged 280E reform in recent earnings calls as the threshold event that would accelerate capital allocation toward growth initiatives versus debt service obligations — a shift that would materially improve free cash flow profiles and investor return metrics.
Secondary market dynamics remain supportive across key state-level markets. Illinois continues to generate strong tax revenue and steady same-store sales growth for its licensed multi-state operators. Pennsylvania’s adult-use transition, which remains in active legislative discussion, could represent a significant near-term catalyst for operators with established medical infrastructure in the state. New York’s adult-use rollout, while slower than initially projected, continues to mature as licensed dispensary infrastructure expands across the five boroughs and upstate markets.
Florida’s failed 2024 adult-use ballot initiative did not reverse the underlying medical market trajectory, and operators with established retail footprints in the state — including Trulieve, Curaleaf, and AYR Wellness — are demonstrating relative resilience in same-store sales data relative to operators without significant Sunshine State exposure.
Conclusion
Friday’s MSOS advance to $4.5550 confirms the week ended on a constructive note for the domestic cannabis sector, with the benchmark fund posting a clean 2.13 percent gain on a day when below-average volume supports the interpretation of steady accumulation rather than reactive momentum. The immediate catalyst focus shifts decisively to the August earnings window, where results from Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings will calibrate market expectations for the balance of 2026 and into the early-2027 planning horizon.
Investors monitoring sector positioning ahead of the August earnings cluster can track real-time cannabis equity performance and sector benchmark data via the cannabis stock tracker. The structural investment case remains intact; near-term volatility will likely concentrate around individual earnings prints rather than macro-level sector sentiment shifts.